Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero(United Biscuits (United Kingdom)), Anthony Letai(Dana-Farber Cancer Institute), Philip C. Amrein(Massachusetts General Hospital), Kristopher A. Sarosiek(Harvard University), Pasi A. Jänne(Harvard University), Jeremy Ryan(Dana-Farber Cancer Institute), Ursula A. Matulonis(Dana-Farber Cancer Institute), Ronny Drapkin(University of Pennsylvania), Ross S. Berkowitz(Dana-Farber Brigham Cancer Center), Neil S. Horowitz(Brigham and Women's Hospital), Ophélia Maertens(American Institutes for Research), Joseph D. DeAngelo, Dalia Ercan(Dana-Farber Cancer Institute), Huiying Piao(Brigham and Women's Hospital), Karen Cichowski(Brigham and Women's Hospital)
Cited by 377
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k